"While the rescinded grant is undoubtedly a setback, it also sharpens our focus on the solid foundation already established ...

The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

A Massachusetts-based wound care and sports medicine company announced plans for its brand-new biomanufacturing facility ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

FBT ETF launched 19 years ago and has delivered exceptional returns compared to the broader Health Care sector. Read why FBT ...

The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

Point Loma Nazarene University has launched the Biotech Pathway Scholarship, which covers full tuition and fees for two years ...

The Bay Area's biotech industry faces an uncertain future after 50 years. But industry leaders see a history of resilience ...

Microsoft, Chevron, 10x Genomics, 23andMe, NetApp, NGM Biopharmaceuticals, Pliant Therapeutics and Downtown College Prep are ...

Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter ...

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...